Apellis Pharmaceuticals ROCE 2024

Apellis Pharmaceuticals Aktienanalyse

What does Apellis Pharmaceuticals do?

Apellis Pharmaceuticals was founded in 2009 and is headquartered in Waltham, Massachusetts, USA. The company is a biopharmaceutical company specializing in developing innovative therapies for serious diseases of the immune system and the eyes. The company's focus is on developing therapies for rare and difficult-to-treat diseases. Apellis relies on a cellular science platform based on the discovery of new biological mechanisms. In the field of ophthalmology, Apellis is developing therapies for rare retinal diseases such as geographic atrophy, a progressive disease that can lead to blindness. The company has developed a new drug called APL-2, which is currently being tested in clinical trials. APL-2 inhibits the complement system, an important component of the immune system that plays a crucial role in retinal diseases. In the field of immunology, Apellis is working on developing therapies for autoimmune diseases, where the immune system attacks the body's own tissues. One such disease is paroxysmal nocturnal hemoglobinuria (PNH), which can lead to destruction of red blood cells. Apellis has developed a drug called APL-2, which inhibits the complement system and stops the breakdown of red blood cells. APL-2 is also being investigated for other autoimmune diseases such as the rare blood disorder syndrome, thrombotic microangiopathy syndrome. Apellis is also developing a therapy for chronic obstructive pulmonary disease (COPD), which can cause survival problems in advanced stages. The research focus is on identifying targets in the complement system and developing therapeutics to inhibit these targets. Apellis' business model is based on a collaborative approach, working closely with patient support groups to better understand patient needs and develop a deep physiological understanding of disease mechanisms to explore more effective therapy approaches. Apellis also collaborates with biotechnology partners and suppliers to accelerate the development of its drugs and reduce costs. Apellis has a strong financing base and has conducted several successful investment rounds in recent years. In 2017, the company raised $150 million in a Series E investment round. In 2019, Apellis received a $250 million investment from Swiss Re, one of the world's largest reinsurance companies, for a 10% stake in the company. This investment provides Apellis with the financial stability necessary for accelerated drug development. In 2020, Apellis obtained approval for APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in the EU. In the same year, the company also obtained accelerated approval for APL-2 for the treatment of synergenic constipation syndrome. In summary, Apellis Pharmaceuticals is an innovative biopharmaceutical company specializing in the development of therapies for rare and difficult-to-treat diseases of the immune system and the eyes. With a strong financing base and a wide range of products, the company is well positioned to fully leverage the potential of its cellular science platform and provide innovative treatment options for patients. Apellis Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Apellis Pharmaceuticals's Return on Capital Employed (ROCE)

Apellis Pharmaceuticals's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Apellis Pharmaceuticals's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Apellis Pharmaceuticals's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Apellis Pharmaceuticals’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Apellis Pharmaceuticals Stock

What is the ROCE (Return on Capital Employed) of Apellis Pharmaceuticals this year?

The ROCE of Apellis Pharmaceuticals is -2.66 undefined this year.

How has the ROCE (Return on Capital Employed) of Apellis Pharmaceuticals developed compared to the previous year?

The ROCE of Apellis Pharmaceuticals has increased by -24.04% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Apellis Pharmaceuticals?

A high Return on Capital Employed (ROCE) indicates that Apellis Pharmaceuticals has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Apellis Pharmaceuticals?

A low ROCE (Return on Capital Employed) can indicate that Apellis Pharmaceuticals has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Apellis Pharmaceuticals impact the company?

An increase in the ROCE of Apellis Pharmaceuticals can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Apellis Pharmaceuticals affect the company?

A decrease in ROCE of Apellis Pharmaceuticals can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Apellis Pharmaceuticals?

Some factors that can affect Apellis Pharmaceuticals's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Apellis Pharmaceuticals so important for investors?

The ROCE of Apellis Pharmaceuticals is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Apellis Pharmaceuticals take to improve the ROCE?

To improve the ROCE, Apellis Pharmaceuticals can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Apellis Pharmaceuticals pay?

Over the past 12 months, Apellis Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Apellis Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Apellis Pharmaceuticals?

The current dividend yield of Apellis Pharmaceuticals is .

When does Apellis Pharmaceuticals pay dividends?

Apellis Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Apellis Pharmaceuticals?

Apellis Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Apellis Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Apellis Pharmaceuticals located?

Apellis Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Apellis Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Apellis Pharmaceuticals from 6/30/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 6/30/2024.

When did Apellis Pharmaceuticals pay the last dividend?

The last dividend was paid out on 6/30/2024.

What was the dividend of Apellis Pharmaceuticals in the year 2023?

In the year 2023, Apellis Pharmaceuticals distributed 0 USD as dividends.

In which currency does Apellis Pharmaceuticals pay out the dividend?

The dividends of Apellis Pharmaceuticals are distributed in USD.